DIABETES JOURNAL CLUB MARCH 15, 2012 MARGAUX AÑEL-TIANGCO, MD.

Slides:



Advertisements
Similar presentations
Age-Adjusted Prevalence of Diagnosed Diabetes Among U.S. Adults
Advertisements

Nallasamy K, Jayashree M, Singhi S, Bansal A
Dr. Chris Cobourn Medical Director and Surgeon Surgical Weight Loss Centre Staff Surgeon Trillium Health Centre Mississauga, Ontario.
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
Changes in levels of haemoglobin A 1c during the first 6 years after diagnosis of clinical type 2 diabetes Clinical implications Niels de Fine Olivarius.
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.
Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.
Obesity & Supplements The Fight Against Body Fat - Michael Dellogono -
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Metabolic effects Diabetes
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
 Introduction  Define and describe childhood obesity  Discuss which populations are at risk  Comparison of past and present  Describe medical conditions.
Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.
Routine Care Treatment of Type 2 Diabetes in Germany (DETECT Study) Tatjana Stojakovic 1, Hubert Scharnagl 1, Franz Freisinger 1, Andreas Tiran 1, David.
Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.
After eating, most food is turned into glucose, the body’s main source of energy. What Happens When We Eat? American Diabetes Association.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.
Diabetes Spring 2014.
Diabetes Prevention Program (DPP)
Marwan Ahmed Dr George Muntingh Prof Paul Rheeder
/ 161 Saudi Diploma in Family Medicine Center of Post Graduate Studies in Family Medicine EBM Therapy Articles Dr. Zekeriya Aktürk
1 Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough FDA ADVISORY COMMITTEE 5/11/01.
Spring  There are two types of diabetes ◦ Type 1 and 2  Blood sugar is involved  Insulin is involved  You might need to take your blood sugar.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Gerti Tashko, M.D. DM Journal Club 12/16/2010. The use of exenatide with insulin is not FDA approved. The study was designed to evaluate if exenatide.
DIABETES JOURNAL CLUB FEBRUARY 16, 2012 Margaux Añel-Tiangco, MD.
Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.
Risk Factors for Lower Extremity Ulcer in the Morbidly Obese Diabetics Elly Budiman-Mak MD, MPH, MS. 1,2 Min–Woong Sohn, Ph.D. 1,3 Rodney M. Stuck, DPM.
CDC’s Division of Diabetes Translation. United States Diabetes Surveillance System available at Obesity (BMI≥30 kg/m 2.
PMP Outcomes. Background to Chronic Pain One of the most prevalent physical complaints - defined as prolonged pain of at least 3 months’ duration 10-20%
Copyright © 2015 by the American Osteopathic Association.
Diabetes Journal Club Carina Signori 1/19/2012
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
Nallasamy K, Jayashree M, Singhi S, Bansal A
ACCORD Design and Baseline Characteristics
2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2
Key publication slides
Diabetes and Obesity Journal Club Carina Signori, D.O., M.P.H.
Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD 
Placebo Metformin ***p < vs placebo
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Program Goals. Out of the Periphery and Into Comprehensive Care: Managing Diabetic Peripheral Neuropathy.
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Differentiating Drug-Seeking Behavior From Poorly Controlled Pain
EFFICACY AND MECHANISM
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
Diabetes Journal Club January 19, 2012 Margaux Añel-Tiangco, MD
The Parkinson's Disease Psychosis Journal Club
Insights into Insulin Treatment Challenges: Real-World Evidence and Clinical Trial Data.
The Burden of Modifiable Risk Factors in Newly Defined Categories of Blood Pressure  Anna Gu, MD, PhD, Yu Yue, PhD, Joohae Kim, PharmD Candidate, Edgar.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Diabetes Journal Club March 17, 2011
Cholesterol Management in HIV-infected and Uninfected Patients: The Veterans Aging Cohort Study Leaf, DA, Goulet J, Goetz MB, Oursler KA, Gilbert C, Frieberg.
The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.
Metformin and Vitamin B12 deficiency
New Lipid-Lowering Guidelines
Prevalence of BZD & Other Respiratory Depressing Agents, n=58
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
Persistent organic pollutants and diabetes - Spearman correlation coefficients* among six POPs with age, sex, race and ethnicity, poverty income.
The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.
Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.
Dyslipidemia And Diabetes
Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence.
Schematic representation of the sequelae of overweight/obesity and type 2 diabetes with regard to neuropathy and GERD. A positive feedback exists among.
Twice daily regimen N=45 MDI regimen N=28 P Value
Current challenges in photoprotection
Presentation transcript:

DIABETES JOURNAL CLUB MARCH 15, 2012 MARGAUX AÑEL-TIANGCO, MD

Introduction Prevalence of DM among adults ≥ 65 years = 21.2% Prevalence of B12 deficiency in adults ≥ 60 years = 6% Prevalence of borderline B12 deficiency in adults ≥ 60 years = 20% DeFronzo and Goodman 1995 (First metformin efficacy trial)  Metformin lowered B12 level by 22% vs. placebo, 29% vs. glyburide after 29 wks of treatment

Demographic data

Definition of Terms B12 deficiency ≤ 148 pmol/L Borderline B12 deficiency pmol/L Normal >221 pmol/L B12 intake categories:  0-6 µg – amount typically found in OTC MVI  >6-25 µg – amount typically found in MVI for senior adults

Results T2DM on Metformin T2DM not on Metformin No DM

Table 2 Interpretation For those without DM, B12 supplements assoc. with  ~66.7% lower prevalence of B12 deficiency and borderline def. For those with DM on Metformin, supplements  not assoc. with decrease in the prevalence of B12 deficiency and borderline def. Among metformin users who used supplements  >0-6 µg B12 had prevalence of deficiency of 14.1%  > 6 µg B12 had prevalence of deficiency of 1.8%*

Results Metformin therapy was associated with  B12 deficiency (OR 2.89, 95% CI)  Borderline B12 deficiency (OR 2.32, 95% CI) *even after adjusting for BMI, insulin, and supplement use Among those with T2DM  B12 supplements protective against borderline but not biochemical B12 deficiency Among those without T2DM  B12 supplements were ~70% protective against biochemical B12 deficiency and borderline deficiency

Conclusions Metformin use is associated with B12 deficiency B12 supplements in OTC MVI decrease the prevalence of B12 deficiency in those without DM but not in those with T2DM Pts with T2DM not on metformin had the lowest prevalence of B12 deficiency  May seek medical care more frequently so are better treated for B12 deficiency than other groups  Or these pts may have been switched from metformin to other DM therapies that may increase B12 levles

Limitations Cross-sectional survey – association only and not causation May have included Type 1 DM patients

Take Home Points In the diabetic on metformin who complains of  Neuropathy  Fatigue  Depression  Cognitive impairement Think B12 deficiency.Think B12 deficiency. Screen and treat aggressively!Screen and treat aggressively!

Questions?